Welcome to our dedicated page for Joint SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Joint Corp. (NASDAQ: JYNT) files a range of reports and disclosures with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a national operator, manager and franchisor of chiropractic clinics. These SEC filings cover its Franchise Operations segment, refranchising activity, regional developer arrangements, credit facilities and stock repurchase programs, among other topics relevant to shareholders and analysts.
On this page, you can review The Joint Corp.’s key filings, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss its retail healthcare business model, classification as a lessor of nonfinancial intangible assets, and the performance of its franchised and company-owned or managed clinics. Current reports on Form 8-K provide timely disclosure of material events, such as asset purchase agreements to sell groups of clinics to franchisees, the acquisition or modification of regional developer rights, amendments to its revolving credit agreement, and board authorizations for additional stock repurchase capacity.
Filings also address accounting and reporting matters, including restatements of previously issued financial statements and related internal control considerations, as well as separation agreements with certain officers. Together, these documents outline how The Joint Corp. structures its franchise and management arrangements, manages its balance sheet and capital allocation, and responds to regulatory and governance requirements.
Stock Titan enhances access to these disclosures with real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the significance of complex filings. Users can quickly identify information related to refranchising transactions, development rights, credit facility amendments and other material events affecting JYNT, without reading every line of each report.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G for Joint Corp/The reporting that, after an internal realignment, its filing shows 0 shares beneficially owned and 0% of the class. The amendment cites the January 12, 2026 realignment and SEC Release No. 34-39538 to explain that certain Vanguard subsidiaries will report ownership separately.
The filing lists the issuer as Joint Corp/The (principal executive offices at 16767 N Perimeter Dr, Suite 110, Scottsdale, AZ) and is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
Bandera Partners and affiliated investors updated their ownership disclosure in The Joint Corp. They may be deemed to beneficially own 3,937,296 shares of common stock, representing about 27.9% of the company based on 14,114,334 shares outstanding as of March 9, 2026.
The higher ownership percentage results solely from a decrease in total shares outstanding, not from new purchases or sales. The filing states that no reporting person has traded The Joint Corp. securities in the past 60 days.
The Joint Corp. files its Annual Report describing a large, highly franchised chiropractic network and a shift toward a pure-play franchisor model. The company operated 960 clinics in 43 states as of December 31, 2025 and delivered over 14.4 million patient visits in 2025.
System-wide sales reached $532.4 million in 2025, up sharply from $22.3 million in 2012, while 2025 same-store sales were flat in percentage terms. The Joint emphasizes a cash-based, non-insurance model with average adjustment prices around $37, about 51% below industry averages, and collects a 7% royalty and 2% marketing fee from franchisees.
Management highlights continued growth through franchise sales, opening clinics already in development, and refranchising all company-owned or managed clinics, supported by an experienced leadership team. Key risks include nationwide labor shortages, inflation-driven wage pressure, tighter credit, and evolving privacy, cybersecurity and state-level corporate practice regulations.
The Joint Corp. reported a return to profitability for 2025 while accelerating its shift to a franchisor model. Full-year revenue rose to $54.9 million from $52.2 million, with consolidated net income improving to $2.9 million from a loss of $5.8 million. Consolidated Adjusted EBITDA increased 13.9% to $13.0 million.
In the fourth quarter, revenue grew 3.1% to $15.2 million and net income reached $1.0 million. System-wide sales for 2025 were $532.4 million, though comp sales declined 0.4%. The company refranchised 41 clinics, ended the year with 960 locations, and repurchased 1.3 million shares for $11.3 million.
For 2026, guidance calls for system-wide sales between $519 million and $552 million, system-wide comp sales between (3)% and 3%, consolidated Adjusted EBITDA of $12.5–$13.5 million, and 30–35 new franchised clinic openings as it completes its transition to a capital-light, pure-play franchisor model.
Bowman Scott Justin reported acquisition or exercise transactions in this Form 4 filing.
JOINT Corp disclosed that Chief Financial Officer Scott Justin Bowman received a grant of 28,301 shares of common stock as a stock award. These shares are restricted, with 25% scheduled to vest on each of the first four anniversaries of the grant date. Following this award, Bowman directly holds 48,285 common shares.
Razdan Sanjiv Kumar reported acquisition or exercise transactions in this Form 4 filing.
JOINT Corp director and officer Sanjiv Kumar Razdan received a grant of 73,484 shares of Common Stock as a stock award, with no cash paid per share. All of these are restricted shares that vest in four equal installments of 25% on each of the first four anniversaries of the grant date.
After this award, Razdan directly holds 162,516 shares of JOINT Corp common stock. Because this is a compensation-related grant rather than an open-market purchase, it reflects equity-based pay designed to align his interests with shareholders over the multi‑year vesting period.
Joint Corp 10% owner Charles E. Jobson reported an open-market purchase of 15,397 common shares at $8.50 each on February 12, 2026. Following this transaction, he directly holds 1,645,294 common shares. The filing also corrects a previously misstated ownership figure from November 20, 2025.
JOBSON CHARLES E, a more than 10% owner of The Joint Corp. (JYNT), bought additional common shares in an open-market transaction. On February 11, 2026, he purchased 448 common shares at $8.70 per share. Following this trade, he directly owned 1,639,597 common shares.
JOINT Corp’s 10% owner Charles E. Jobson reported open‑market purchases of common stock. He bought 16,753 shares of common stock at $10 per share on January 23, 2026, and 725 shares at $10 per share on January 26, 2026.
After these transactions, Jobson directly owned 1,639,149 shares of JOINT Corp common stock.
The Joint Corp. filed an amended current report to correct its description of a letter agreement with Bandera Partners LLC and Jefferson Gramm. Under the revised summary, the company agreed to include Mr. Gramm in its slate of director nominees for the 2026 annual meeting and to recommend that stockholders vote for his election. Bandera agreed that, until a defined termination date, it will not increase its beneficial ownership above the 3,937,296 shares of common stock it already holds, excluding any equity awards tied to Mr. Gramm’s board service. The agreement lasts until the earlier of thirty days before the nomination notice deadline for the 2027 annual meeting or January 21, 2027.